SR ONE CAPITAL MANAGEMENT, LP Q2 2024 Filing
Filed August 13, 2024
Portfolio Value
$319.4B
Holdings
9
Report Date
Q2 2024
Filing Type
13F-HR
All Holdings (9 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ACLXArcellx, Inc. | 2,346,630 | $129.5B | 40.55% | |
| 2 | CRSPCRISPR Therapeutics AG | 1,048,951 | $56.7B | 17.74% | |
| 3 | SPRYARS Pharmaceuticals, Inc. | 4,012,903 | $34.1B | 10.69% | |
| 4 | ALMSAlumis Inc. | 1,959,896 | $26.1B | 8.16% | |
| 5 | MLYSMineralys Therapeutics Inc. | 2,016,822 | $23.6B | 7.39% | |
| 6 | DSGNDesign Therapeutics, Inc. | 6,526,476 | $21.9B | 6.85% | |
| 7 | NKTXNkarta, Inc. | 3,333,333 | $19.7B | 6.17% | |
| 8 | ENGNenGene Holdings Inc. | 500,000 | $4.7B | 1.48% | |
| 9 | KALAKALA Bio, Inc. | 443,661 | $3.1B | 0.98% |